title: The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review.
abstract: A systematic review was performed to describe the findings from 19 genetic association studies that have examined the genetic variants underlying four common treatment-induced chronic and late toxicities in breast cancer patients, and to evaluate the quality of reporting. Three out of 5 studies found an association between HER2 lle655Val polymorphisms and trastuzumab-induced cardiotoxicity. Two studies found a positive association between cognitive impairment and the Val allele of the COMT gene and the ε4 allele of the apolipoprotein E gene. Genetic associations were established between fatigue and the G/G genotype of IL6-174 and TNF-308, and the Met allele of the COMT gene in 4 studies. Among studies (N=8) that evaluated the genetic associations underlying peripheral neuropathy, CYP2C8∗3 variant is commonly reported as the associated gene. Most studies failed to conform to the major criteria listed in the STREGA guidelines, with a lack of transparent reporting of methods and results.
authors.affiliation: Department of Pharmacy, National University of Singapore, Singapore.
authors.forename: Terence
authors.initials: T
authors.lastname: Ng
authors.affiliation: Department of Pharmacy, National University of Singapore, Singapore.
authors.forename: Mint
authors.initials: M
authors.lastname: Chan
authors.affiliation: Human Genetics, Genome Institute of Singapore, Singapore.
authors.forename: Chiea Chuen
authors.initials: CC
authors.lastname: Khor
authors.affiliation: Department of Pharmacy, National University of Singapore, Singapore.
authors.forename: Han Kiat
authors.initials: HK
authors.lastname: Ho
authors.affiliation: Department of Pharmacy, National University of Singapore, Singapore; Department of Pharmacy, National Cancer Centre Singapore, Singapore. Electronic address: phaac@nus.edu.sg.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Chan
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001057:Apolipoproteins E / Q000235:genetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000235:genetics; D002394:Catechol O-Methyltransferase / Q000235:genetics; D003072:Cognition Disorders / Q000139:chemically induced* / Q000235:genetics; D065727:Cytochrome P-450 CYP2C8 / Q000235:genetics; D005221:Fatigue / Q000139:chemically induced* / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000235:genetics; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D001057:Apolipoproteins E; D001189:Aryl Hydrocarbon Hydroxylases; D002394:Catechol O-Methyltransferase; D065727:Cytochrome P-450 CYP2C8; D015850:Interleukin-6; D018719:Erb-b2 Receptor Tyrosine Kinases; C508600:IL6 protein, human; C450259:CYP2C8 protein, human; C588010:COMT protein, human; C508053:ERBB2 protein, human
keywords: Breast cancer; Cardiotoxicity; Cognitive dysfunction; Fatigue; Genetic association; Peripheral neuropathy